Validating the effect of Ondansetron and Mirtazapine In Treating hyperemesis gravidarum (VOMIT): protocol for a randomised placebo-controlled trial

Anne Ostenfeld, Tonny Studsgaard Petersen, Tina Bergmann Futtrup, Jon Trærup Andersen, Andreas Kryger Jensen, Hanne Brix Westergaard, Lars Henning Pedersen, Ellen Christine Leth Løkkegaard, Anne Ostenfeld, Tonny Studsgaard Petersen, Tina Bergmann Futtrup, Jon Trærup Andersen, Andreas Kryger Jensen, Hanne Brix Westergaard, Lars Henning Pedersen, Ellen Christine Leth Løkkegaard

Abstract

Introduction: Current pharmacological treatment options for hyperemesis gravidarum have been introduced based on scarce evidence and are often not sufficiently effective. Several case reports suggest that mirtazapine, an antidepressant, may be an effective treatment for hyperemesis gravidarum, but so far there are no controlled trials investigating the potential effect of mirtazapine on hyperemesis gravidarum. The antiemetic ondansetron is currently widely used to treat hyperemesis gravidarum despite sparse evidence of effect in pregnant women. This study aims to investigate the effect of mirtazapine on hyperemesis gravidarum while also providing data on the effect of ondansetron.

Methods and analysis: This randomised double-blind placebo-controlled multicentre trial will be conducted in eight Danish hospitals. One hundred and eighty pregnant women referred to secondary care for hyperemesis gravidarum will be randomly allocated to 14-day treatment with either mirtazapine, ondansetron or placebo. Main inclusion criterion will be Pregnancy Unique Quantification of Emesis (PUQE-24) score ≥13 or PUQE-24 score ≥7 if accompanied by weight loss >5% of pre-pregnancy weight or hospitalisation. Participants are eligible regardless of whether other antiemetics, including ondansetron, have been tried. The coprimary outcomes are effects of mirtazapine and ondansetron, respectively, on PUQE-24 score tested hierarchically on day 2 and day 14. Secondary outcomes include, but are not limited to, differences between the three groups in number of daily vomiting episodes, dropout due to treatment failure, use of rescue medication, weight change and side effects.

Ethics and dissemination: The trial has been approved by the Regional Committees on Health Research Ethics in the Capital Region of Denmark, the Danish Medicines Agency and the Danish Data Protection Agency. Results will be published in peer-reviewed journals and submitted to relevant conferences.

Trial registration number: NCT03785691.

Keywords: clinical trials; gynaecology; maternal medicine; obstetrics.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Trial design.

References

    1. Gazmararian JA, Petersen R, Jamieson DJ, et al. . Hospitalizations during pregnancy among managed care enrollees. Obstet Gynecol 2002;100:94–100.10.1016/s0029-7844(02)02024-0
    1. Einarson TR, Piwko C, Koren G. Quantifying the global rates of nausea and vomiting of pregnancy: a meta analysis. J Popul Ther Clin Pharmacol 2013;20:e171-83.
    1. Koot MH, Boelig RC, Van't Hooft J, et al. . Variation in hyperemesis gravidarum definition and outcome reporting in randomised clinical trials: a systematic review. BJOG 2018;125:1514–21.10.1111/1471-0528.15272
    1. London V, Grube S, Sherer DM, et al. . Hyperemesis gravidarum: a review of recent literature. Pharmacology 2017;100:161–71.10.1159/000477853
    1. Dodds L, Fell DB, Joseph KS, et al. . Outcomes of pregnancies complicated by hyperemesis gravidarum. Obstet Gynecol 2006;107:285–92.10.1097/
    1. Heitmann K, Nordeng H, Havnen GC, et al. . The burden of nausea and vomiting during pregnancy: severe impacts on quality of life, daily life functioning and willingness to become pregnant again - results from a cross-sectional study. BMC Pregnancy Childbirth 2017;17:7510.1186/s12884-017-1249-0
    1. Poursharif B, Korst LM, Macgibbon KW, et al. . Elective pregnancy termination in a large cohort of women with hyperemesis gravidarum. Contraception 2007;76:451–5.10.1016/j.contraception.2007.08.009
    1. Boelig RC, Barton SJ, Saccone G, et al. . Interventions for treating hyperemesis gravidarum: a Cochrane systematic review and meta-analysis. J Matern Fetal Neonatal Med 2018;31:2492–505.10.1080/14767058.2017.1342805
    1. Taylor LG, Bird ST, Sahin L, et al. . Antiemetic use among pregnant women in the United States: the escalating use of ondansetron. Pharmacoepidemiol Drug Saf 2017;26:592–6.10.1002/pds.4185
    1. Kashifard M, Basirat Z, Kashifard M, et al. . Ondansetrone or metoclopromide? which is more effective in severe nausea and vomiting of pregnancy? A randomized trial double-blind study. Clin Exp Obstet Gynecol 2013;40:127–30.
    1. Oliveira LG, Capp SM, You WB, et al. . Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial. Obstet Gynecol 2014;124:735–42.10.1097/AOG.0000000000000479
    1. Abramowitz A, Miller ES, Wisner KL. Treatment options for hyperemesis gravidarum. Arch Womens Ment Health 2017;20:363–72.10.1007/s00737-016-0707-4
    1. Benjamin S, Doraiswamy PM. Review of the use of mirtazapine in the treatment of depression. Expert Opin Pharmacother 2011;12:1623–32.10.1517/14656566.2011.585459
    1. Omay O, Einarson A. Is mirtazapine an effective treatment for nausea and vomiting of pregnancy?: a case series. J Clin Psychopharmacol 2017;37:260–1.10.1097/JCP.0000000000000656
    1. Dorn C, Pantlen A, Rohde A. Mirtazapin (Remergil®): Behandlungsoption bei therapieresistenter Hyperemesis gravidarum? - ein Fallbericht. Geburtshilfe Frauenheilkd 2002;62:677–80.10.1055/s-2002-33014
    1. Guclu S, Gol M, Dogan E, et al. . Mirtazapine use in resistant hyperemesis gravidarum: report of three cases and review of the literature. Arch Gynecol Obstet 2005;272:298–300.10.1007/s00404-005-0007-0
    1. Rohde A, Dembinski J, Dorn C, Mirtazapine DC. Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy. Arch Gynecol Obstet 2003;268:219–21.10.1007/s00404-003-0502-0
    1. Saks BR. Mirtazapine: treatment of depression, anxiety, and hyperemesis gravidarum in the pregnant patient. A report of 7 cases. Arch Womens Ment Health 2001;3:165–70.10.1007/s007370170014
    1. Schwarzer V, Heep A, Gembruch U, et al. . Treatment resistant hyperemesis gravidarum in a patient with type 1 diabetes mellitus: neonatal withdrawal symptoms after successful antiemetic therapy with mirtazapine. Arch Gynecol Obstet 2008;277:67–9.10.1007/s00404-007-0406-5
    1. Uguz F. Low-Dose mirtazapine in treatment of major depression developed following severe nausea and vomiting during pregnancy: two cases. Gen Hosp Psychiatry 2014;36:e5–6.10.1016/j.genhosppsych.2013.07.016
    1. Uguz F. Low-Dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases. J Matern Fetal Neonatal Med 2013;26:1066–8.10.3109/14767058.2013.766697
    1. Lieb M, Palm U, Jacoby D, et al. . [Mirtazapine and hyperemesis gravidarum]. Nervenarzt 2012;83:374–6.10.1007/s00115-011-3297-4
    1. Bhattacharjee D, Doleman B, Lund J, et al. . Mirtazapine for postoperative nausea and vomiting: systematic review, meta-analysis, and trial sequential analysis. J Perianesth Nurs 2019;34:680–90.10.1016/j.jopan.2018.11.006
    1. Ebrahimi N, Maltepe C, Bournissen FG, et al. . Nausea and vomiting of pregnancy: using the 24-hour Pregnancy-Unique quantification of emesis (PUQE-24) scale. J Obstet Gynaecol Can 2009;31:803–7.10.1016/S1701-2163(16)34298-0
    1. Harris PA, Taylor R, Thielke R, et al. . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81.10.1016/j.jbi.2008.08.010
    1. Koren G, Clark S, Hankins GDV, et al. . Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. Am J Obstet Gynecol 2010;203:e1–7.10.1016/j.ajog.2010.07.030
    1. Smit M, Dolman KM, Honig A. Mirtazapine in pregnancy and lactation - A systematic review. Eur Neuropsychopharmacol 2016;26:126–35.10.1016/j.euroneuro.2015.06.014
    1. Winterfeld U, Klinger G, Panchaud A, et al. . Pregnancy outcome following maternal exposure to mirtazapine. J Clin Psychopharmacol 2015;35:250–9.10.1097/JCP.0000000000000309
    1. Ingadottir G, Hedegaard L, Poulsen H. Maternal exposure to mirtazapine in the first trimester and the risk of congenital malformations – a nationwide cohort study [abstract], 2016.
    1. Janusinfo Läkemedel och fosterpåverken. Available: [Accessed 1 Oct 2019].
    1. Smit M, Wennink H, Heres M, et al. . Mirtazapine in pregnancy and lactation: data from a case series. J Clin Psychopharmacol 2015;35:163–7.10.1097/JCP.0000000000000279
    1. Carstairs SD. Ondansetron use in pregnancy and birth defects: a systematic review. Obstet Gynecol 2016;127:878–83.10.1097/AOG.0000000000001388
    1. Huybrechts KF, Hernández-Díaz S, Straub L, et al. . Association of maternal first-trimester ondansetron use with cardiac malformations and oral clefts in offspring. JAMA 2018;320:242910.1001/jama.2018.18307
    1. Huybrechts KF, Hernandez-Diaz S, Straub L, et al. . Intravenous ondansetron in pregnancy and risk of congenital malformations. JAMA 2019;25:2019–21.10.1001/jama.2019.18587
    1. Niemeijer MN, Grooten IJ, Vos N, et al. . Diagnostic markers for hyperemesis gravidarum: a systematic review and metaanalysis. Am J Obstet Gynecol 2014;211:e1–15.10.1016/j.ajog.2014.02.012
    1. Dean CR, Shemar M, Ostrowski GAU, et al. . Management of severe pregnancy sickness and hyperemesis gravidarum. BMJ 2018;363:k500010.1136/bmj.k5000
    1. DSOG Hyperemesis Gravidarum - Guideline - DSOG, 2013. Available:
    1. Grooten IJ, Koot MH, van der Post JA, et al. . Early enteral tube feeding in optimizing treatment of hyperemesis gravidarum: the maternal and offspring outcomes after treatment of hyperemesis by refeeding (mother) randomized controlled trial. Am J Clin Nutr 2017;106:ajcn158931–2.10.3945/ajcn.117.158931
    1. Persaud N, Meaney C, El-Emam K, et al. . Doxylamine-Pyridoxine for nausea and vomiting of pregnancy randomized placebo controlled trial: Prespecified analyses and reanalysis. PLoS One 2018;13:e0189978–19.10.1371/journal.pone.0189978

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅